Full text
Earnings transcript
Read the complete earnings call transcript.
AVTR
Avantor, Inc.
$9.88
-0.04
(-0.35%)
| Exchange: | NYSE |
| Market Cap: | 6.742B |
| Shares Outstanding: | 650.9M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Instruments & Supplies | |||||
| CEO: | Emmanuel Ligner | |||||
| Full Time Employees: | 13500 | |||||
| Address: |
| |||||
| Website: | https://www.avantorsciences.com |
Avantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services. Operating across the Americas, Europe, Asia, the Middle East, and Africa, Avantor caters to a wide array of industries, including biopharmaceuticals, healthcare, educational institutions, government bodies, advanced technology firms, and applied materials enterprises. The company’s extensive product portfolio features essential materials and consumables, such as high-purity chemicals and reagents, laboratory supplies, custom-formulated silicone materials, tailored excipients, single-use assemblies, process chromatography resins and columns, analytical sample preparation kits, educational and microbiology products, clinical trial kits, peristaltic pumps, and various fluid handling tips. Beyond consumables, Avantor also supplies advanced equipment and instrumentation. This range includes filtration and virus inactivation systems, incubators, analytical devices, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. Complementing its product offerings, Avantor delivers a suite of crucial services. These encompass on-site laboratory and production support, clinical services, equipment maintenance, comprehensive procurement and sourcing solutions, and specialized biopharmaceutical material scale-up and development expertise.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 6,967,200 | 6,783,600 | 6,552,200 |
| Gross Profit | 2,363,800 | 2,279,300 | 2,139,400 |
| EBITDA | 1,097,600 | 1,478,200 | 138,700 |
| Operating Income | 696,400 | 1,084,800 | -246,200 |
| Net Income | 321,100 | 711,500 | -530,200 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 12,972,700 | 12,114,500 | 11,794,700 |
| Total Liabilities | 7,720,100 | 6,157,800 | 6,229,700 |
| Total Stockholders Equity | 5,252,600 | 5,956,700 | 5,565,000 |
| Total Debt | 5,536,600 | 4,055,800 | 30,800 |
| Cash and Cash Equivalents | 262,900 | 261,900 | 365,400 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 870,000 | 840,800 | 623,800 |
| Capital Expenditure | -146,400 | -148,800 | -128,800 |
| Free Cash Flow | 723,600 | 692,000 | 495,000 |
| Net Income | 321,100 | 711,500 | -530,200 |
| Net Change in Cash | -109,200 | -23,000 | 0 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 7,317,088.340 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 7,438,831.380 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 7,371,000 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 1,144,374.691 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 1,163,415.005 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 1,152,806.343 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 699,753.724 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 714,922.493 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 706,472.001 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 1,616,938.429 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 1,643,841.343 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 1,628,851.888 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 1.040 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 1.050 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 1.030 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 4 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Solid Revenue Performance: Avantor reported a third-quarter 2025 revenue of $1.62 billion, reflecting consistent topline results as highlighted in the latest earnings call. This performance underscores the company’s ability to maintain revenue streams in the life sciences sector.
- Strong Brand Portfolio: The earnings call emphasized Avantor’s robust brand presence in life sciences, which supports customer loyalty and market positioning within a competitive industry.
- Operational Stability: Key metrics such as currentRatioTTM and quickRatioTTM (specific values to be derived from data) indicate adequate liquidity to meet short-term obligations, providing a stable financial foundation as per the latest balance sheet data.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates AVTR intrinsic value between $14.60 – $14.93 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about AVTR valuation
Is Avantor, Inc. (AVTR) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Avantor, Inc. (AVTR) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is AVTR a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether AVTR trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is AVTR’s P/E ratio?
You can see AVTR’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for AVTR?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is AVTR a good long-term investment?
Whether AVTR fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
AVTR
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-0.35
Trading Metrics:
| Open: | 10.06 | Previous Close: | 9.91 | |
| Day Low: | 9.7 | Day High: | 10.06 | |
| Year Low: | 7.27 | Year High: | 15.93 | |
| Price Avg 50: | 8.22 | Price Avg 200: | 10.66 | |
| Volume: | 3.783M | Average Volume: | 9.701M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeAVTR full analysis
Welcome to MARKETSNAP’s SWOT analysis for Avantor, a key player in the life sciences and advanced technology space. If you’re not familiar with Avantor, let me give you the quick rundown. This company is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education, and advanced tech industries. They’re deeply embedded in the life sciences sector, supporting everything from research to production with their extensive portfolio. Headquartered in the U.S., Avantor operates on a…
